Boston, MA — May 31, 2016 — Media Alert
In “Understanding and Managing Growth,” L.E.K. Managing Director and Head of the Life Sciences and MedTech practice for the Americas, David Barrow, will moderate a panel of distinguished biopharma executives who will discuss transitioning from development-focused to more fully-integrated and commercially-oriented companies. The organizational scale-up requirements and increasing complexity of operations, sometimes across regions, present numerous challenges. This group will share learnings from going through this transformation recently and debate some of the critical trade-offs involved.
In “Is the Rare Diseases Model Sustainable?” Eileen Coveney, senior managing director in L.E.K.’s Life Sciences practice, will lead a discussion with distinguished experts PJ Anand of Alcyone, Ed Mascioli of SV Life Sciences, David Meeker of Sanofi Genzyme, Al Sandrock of Biogen, and Yaron Werber of Ovid Therapeutics.
May 31 – June 1, 2016
Four Seasons Hotel
200 Boylston Street, Boston, MA
May 31, 10:30 — 11 am, Understanding and Managing Growth
May 31, 3:30 — 4 pm, Is the Rare Disease Business Model Sustainable?
About David Barrow:
David Barrow is the Head of the Biopharma, Life Sciences and MedTech practice for the Americas and has more than 18 years of experience in consulting at L.E.K., including corporate strategy development, mergers and acquisitions support, and global commercial planning. As a managing director and partner in our Biopharmaceuticals & Life Sciences and Healthcare Services practices, he has worked on more than 300 assignments with over 100 clients in a variety of sectors, including pharmaceuticals, biotechnology, medical devices, and diagnostics. Barrow has experience across a range of therapeutic areas, including CNS, infectious disease, oncology, and cardiovascular. Before joining L.E.K., he served as a paratrooper and military intelligence officer in the 82nd Airborne Division in the U.S. Army. He received his MBA in Finance from The Wharton School of Business, his Master of Arts in International Studies from The University of Pennsylvania, and his Bachelor of Arts in German from Dartmouth College.
About Eileen Coveney:
Eileen Coveney is a Managing Director and Partner in L.E.K. Consulting’s Biopharma & Life Sciences practice. Eileen has more than 22 years of experience providing strategic advice to leading pharmaceutical and biotechnology companies to develop and execute growth strategies. Her expertise includes corporate strategy, franchise strategy, product opportunity assessment, business development strategy, pricing access and commercial launch planning. Additionally, Eileen leads the firm’s royalty monetization support efforts and has completed more than 50 royalty evaluations, resulting in value-creating transactions for both royalty holders and investors.
Eileen’s therapeutic area experience is comprehensive with particular expertise in orphan drugs, oncology, gastrointestinal conditions, autoimmune diseases, women’s and men’s health, infectious disease and vaccines. She recently spent three years working with global clients in Europe on commercial launch planning and focusing on European pharma. She has held several leadership positions within the firm, most recently as a co-leader of L.E.K.’s U.S. Biopharma & Life Sciences practice.
Eileen earned her Master of Business Administration at Harvard Business School and her Bachelor of Arts in Economics from College of the Holy Cross. Prior to attending business school, she served as a vice president in the Capital Markets Group at Bank of America.
About The Boston Biotech CEO Conference
The Boston Biotech CEO Conference is a networking forum for industry CEOs and decision makers in the life sciences. Attendees gain insights from presentations and panels featuring CEOs from several of the world’s leading biopharmaceutical companies. Industry leaders in venture capital and private equity also participate.
About L.E.K. Consulting:
L.E.K. Consulting is a global management consulting firm that uses deep industry expertise and rigorous analysis to help business leaders achieve practical results with real impact. We are uncompromising in our approach to helping clients consistently make better decisions, deliver improved business performance and create greater shareholder returns. The firm advises and supports global companies that are leaders in their industries — including the largest private and public sector organizations, private equity firms and emerging entrepreneurial businesses. Founded more than 30 years ago, L.E.K. employs more than 1,000 professionals across the Americas, Asia-Pacific and Europe. For more information, go to www.lek.com.